Man found guilty of trafficking hundreds of pounds of drugs through Eastern Washington and Montana
Esquivel-Bolanos (a/k/a 'Colorado') faces a maximum term of imprisonment of life in prison. He may also face removal from the United States at his sentencing in July.
According to a press release from the U.S. Attorney's Office, Esquivel-Bolanos was identified as a member of a drug trafficking organization which had 'flooded' the Eastern District of Washington, including the Oroville area and the Colville Indian Reservation, with methamphetamine and fentanyl. The organization spread as far as central Montana, where many of the illegal drugs were reportedly being sold on Tribal land.
The evidence at trial established that Esquivel-Bolanos helped run the organization, which used threats to maintain control over their drug-distribution activities, such as strip-searching and threatening kill a confidential informant.
According to the attorney's office, on April 19, 2023, BIA, DEA, the North Central Washington Narcotics Task Force, and other federal, state, local, and Tribal law enforcement, executed a series of federal search warrants at several homes in rural Okanogan County, near Oroville, Washington. In total, investigators reportedly seized approximately 161,000 fentanyl-laced pills, 80 pounds of methamphetamine, 6 pounds of heroin, 12 firearms, and more than 2 pounds of cocaine.
'The volume of drugs removed from Eastern Washington and Montana communities, including from Tribal land, is staggering. At the time of Mr. Esquivel-Bolanos's arrest, and even now, the seizure from the Medrano-Bolanos drug trafficking organization was one of the largest ever in rural Washington. I am grateful for the tremendous law enforcement efforts by the BIA, DEA, and others, who put an end to the dangerous and threatening tactics used by Mr. Esquivel-Bolanos and his associates,' said acting U.S. Attorney Richard Barker.
'These agencies came together to address the drug trafficking occurring across many communities in Eastern Washington and Montana, including seven different Indian Reservations,' said Deputy Associate Director Tom Atkinson of the Bureau of Indian Affairs, Division of Drug Enforcement. 'This investigation revealed the purposeful and specific exploitation of Indian Country by the members of this criminal network, illustrating the importance of continued vigilance and cooperation among law enforcement agencies.'
'Mr. Esquivel- Bolanos was second in command of the drug trafficking ring responsible for flooding the Oroville area and Colville Indian Reservation with deadly fentanyl and meth,' said David F. Reames, Special Agent in Charge, DEA Seattle Field Division. 'Drug traffickers who purposely prey on our tribal communities are the worst offenders, and with the help of the jury this Mexican National will be held accountable.'
To learn more about this case, and the twenty-seven defendants that were charged and convicted, visit the U.S. Attorney's Office website.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
DEA Scrambles to Defend Marijuana Decision Amid Supreme Court Ruling, Legal Collapse And Public Outrage
"This Wasn't DEA Marijuana Regulation - It Was a DEA Illegal Ambush." ALL EYES ON TERRY COLE!MMJ BioPharma Cultivation CEO Duane Boise is calling out the DEA's desperate attempt to defend a marijuana Administrative Law Judge decision that never got a hearing, blocked marijuana scientific evidence, and defied Supreme Court precedent. "They're defending a hearing that never actually happened," said Duane Boise."We followed every rule. They followed none." WASHINGTON, D.C. / / July 27, 2025 / Friday, the U.S. Drug Enforcement Administration (DEA) filed a last-minute response in an escalating legal battle with MMJ BioPharma Cultivation, a Rhode Island-based pharmaceutical company seeking to grow federally compliant cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. The agency's filing comes in response to MMJ's official legal "exceptions" challenging a controversial ruling by DEA Chief Administrative Law Judge John Mulrooney II (aka Mclooney) - a ruling that denied MMJ's bulk manufacturing registration without a hearing, without cross-examination, and without admitting material evidence into the record. "We were stonewalled at every step," said Duane Boise, CEO of MMJ BioPharma. "The DEA ignored Supreme Court precedent, blocked our science, and manipulated the process to produce a predetermined outcome. Now they're trying to defend that decision in a system the Department of Justice itself has declared unconstitutional." Constitutional Crisis MMJ's case has become a flashpoint in the broader collapse of the DEA's internal court system. In Axon v. FTC (2023) and Jarkesy v. SEC (2024), the U.S. Supreme Court ruled that agency administrative law judges (ALJs) violate the separation of powers because they are insulated from presidential removal - a direct hit to the DEA's current process. Even the Department of Justice has abandoned its defense of the ALJ structure, and Attorney General Pam Bondi notified the courts in February 2025 that DEA hearings like the one against MMJ BioPharma Cultivation are legally void. DEA's Desperate Defense Despite this, the DEA has now used its one allotted legal filing to respond to MMJ's exceptions - an effort seen by legal experts as a last-ditch attempt to salvage a crumbling decision and maintain bureaucratic control over cannabis based drug development. "This is the DEA doubling down on injustice," said Boise. "They're defending a hearing that never actually happened because they're afraid of what the truth will show." A Legitimate Researcher, Blocked MMJ BioPharma Cultivation is not a dispensary. It is a federally compliant manufacturer that has: FDA Orphan Drug Designation Two accepted Investigational New Drug (IND) applications A pharmaceutical grade cannabis facility built to DEA standards Binding supply agreements with Schedule I licensees Yet after more than 2,400 days of delays, the DEA still refuses to approve its registration - while unlicensed tribal and cartel-linked marijuana networks operate with impunity across state lines, and recreational cannabis companies receive preferential treatment. Path Forward: Will Administrator Terrance Cole Act? All eyes now turn to Terrance Cole, President Trump's newly confirmed DEA Administrator, who holds the final authority to approve or deny MMJ's license. "Administrator Cole has a choice," said Boise. "He can defend a broken system riddled with bias and constitutional violations-or he can restore integrity by granting our lawful, science backed registration and ending seven years of obstruction." MMJ BioPharma has vowed to take its case as far as necessary, including seeking federal injunctions and legislative reform if the DEA continues to block research. About MMJ BioPharma Cultivation MMJ BioPharma is a federally compliant biopharmaceutical company focused on producing cannabis derived medicines for neurodegenerative diseases. It operates under FDA regulatory frameworks and maintains partnerships with international GMP manufacturers and licensed U.S. laboratories. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire
Associated Press
8 hours ago
- Associated Press
DEA Scrambles to Defend Marijuana Decision Amid Supreme Court Ruling, Legal Collapse And Public Outrage
'This Wasn't DEA Marijuana Regulation - It Was a DEA Illegal Ambush.' ALL EYES ON TERRY COLE! MMJ BioPharma Cultivation CEO Duane Boise is calling out the DEA's desperate attempt to defend a marijuana Administrative Law Judge decision that never got a hearing, blocked marijuana scientific evidence, and defied Supreme Court precedent. ' They're defending a hearing that never actually happened,' said Duane Boise.'We followed every rule. They followed none.' WASHINGTON, D.C. / ACCESS Newswire / July 27, 2025 / Friday, the U.S. Drug Enforcement Administration (DEA) filed a last-minute response in an escalating legal battle with MMJ BioPharma Cultivation, a Rhode Island-based pharmaceutical company seeking to grow federally compliant cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. The agency's filing comes in response to MMJ's official legal 'exceptions' challenging a controversial ruling by DEA Chief Administrative Law Judge John Mulrooney II (aka Mclooney) - a ruling that denied MMJ's bulk manufacturing registration without a hearing, without cross-examination, and without admitting material evidence into the record. 'We were stonewalled at every step,' said Duane Boise, CEO of MMJ BioPharma. 'The DEA ignored Supreme Court precedent, blocked our science, and manipulated the process to produce a predetermined outcome. Now they're trying to defend that decision in a system the Department of Justice itself has declared unconstitutional.' Constitutional Crisis MMJ's case has become a flashpoint in the broader collapse of the DEA's internal court system. In Axon v. FTC (2023) and Jarkesy v. SEC (2024), the U.S. Supreme Court ruled that agency administrative law judges (ALJs) violate the separation of powers because they are insulated from presidential removal - a direct hit to the DEA's current process. Even the Department of Justice has abandoned its defense of the ALJ structure, and Attorney General Pam Bondi notified the courts in February 2025 that DEA hearings like the one against MMJ BioPharma Cultivation are legally void. DEA's Desperate Defense Despite this, the DEA has now used its one allotted legal filing to respond to MMJ's exceptions - an effort seen by legal experts as a last-ditch attempt to salvage a crumbling decision and maintain bureaucratic control over cannabis based drug development. 'This is the DEA doubling down on injustice,' said Boise. 'They're defending a hearing that never actually happened because they're afraid of what the truth will show.' A Legitimate Researcher, Blocked MMJ BioPharma Cultivation is not a dispensary. It is a federally compliant manufacturer that has: Yet after more than 2,400 days of delays, the DEA still refuses to approve its registration - while unlicensed tribal and cartel-linked marijuana networks operate with impunity across state lines, and recreational cannabis companies receive preferential treatment. Path Forward: Will Administrator Terrance Cole Act? All eyes now turn to Terrance Cole, President Trump's newly confirmed DEA Administrator, who holds the final authority to approve or deny MMJ's license. 'Administrator Cole has a choice,' said Boise. 'He can defend a broken system riddled with bias and constitutional violations-or he can restore integrity by granting our lawful, science backed registration and ending seven years of obstruction.' MMJ BioPharma has vowed to take its case as far as necessary, including seeking federal injunctions and legislative reform if the DEA continues to block research. About MMJ BioPharma Cultivation MMJ BioPharma is a federally compliant biopharmaceutical company focused on producing cannabis derived medicines for neurodegenerative diseases. It operates under FDA regulatory frameworks and maintains partnerships with international GMP manufacturers and licensed U.S. laboratories. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
Black America Web
2 days ago
- Black America Web
Jeff Teague Walks Back Claim LeBron James Took Steroids During Miami Heat Days, Social Media Reacts
Jeff Teague and his friends-turned-co-host on the Club 520 podcast are known for cracking jokes at the former player's expense and giving hilarious takes and some behind-the-scenes in-game moments. The trio is very unfiltered to say the least, and now Teague may have poked the wrong bear with a recent comment about LeBron James when he was in his prime during his Big Three era with the Miami Heat. He was so dominant those years that Teague joked that he was juicing. 'Miami Heat Bron, he was on steroids bro, he had to sit out because he was on steroids. Allegedly,' Teague said. 'He had to sit out when they started testing for HGH, and he said his back was hurt and sat out for like three weeks and came back skinny. I was in the league, and I remember. He came back, and he was crazy.' The only thing is, it wasn't exactly a joke, because back in 2013, the allegation led to an FBI investigation. The DEA busted Florida's Biogenesis clinic in what became the largest doping operation in U.S. sports history, involving Alex Rodriguez, Nelson Cruz, and WWE star Paul 'The Big Show' Wight. The federal documents consisted of 1,400 pages and included David Alexander, a well-known trainer who had worked with James, as well as the NBA champions' friend and business manager, Ernest 'Randy' Mims, which led to the feds looking into the then Heat star before ultimately clearing him. 'I can tell you that we looked into everything just because we knew this day would come,' the lead DEA investigator concluded, according to ESPN. 'There was never any indication that LeBron James did anything wrong.' Docs do suggest that Mims purchased testosterone — a Schedule III controlled substance — and metabolism-boosting injections, but he claimed they were for himself. Right on time, those proverbial Klutch-branded trucks pulled up on Teague, who issued a clarification on social media. 'Y'all weird I was joking about bron he was just that dominant chill,' he wrote to his Instagram stories. See how social media is reacting to the steroid allegations spinning the block below. Jeff Teague Walks Back Claim LeBron James Took Steroids During Miami Heat Days, Social Media Reacts was originally published on
